A Massachusetts General Hospital (MGH) research team has identified what appears to be an important checkpoint in dietary metabolism, a group of cells in the small intestine that slow down metabolism, increasing the amount of ingested food that is stored as fat rather than being quickly converted into energy. In the report published in Nature they find that mice lacking these cells can consume diets high in fat and sugar without developing conditions like obesity, diabetes, hypertension and heart disease.
"After you eat, your body can convert energy into heat and burn it quickly or it can convert the food into fat and store it for later use," says Filip Swirski, PhD, of the MGH Center for Systems Biology, senior author of the Nature paper. "We often speak of people who have a 'high metabolism' and seem to be able to eat whatever they want without gaining weight, while others struggle with obesity. These cells, which are known for their function in the immune system, also appear to play an important role in that metabolic choice."
The team's study focused on a protein called integrin β7, which is known to direct immune cells to the gut but not previously to have any influence over metabolism. The MGH team initially found that mice lacking the gene for integrin β7 and fed a normal diet gained equal amounts of weight as did a group of control animals, even though the β7-negative animals ate more food and were equally as active. Metabolic testing indicated that the β7-negative mice converted more food into energy, suggesting they had a higher basal metabolism. They also burned more glucose in brown fat, were more glucose tolerant, had lower triglyceride levels and better fat tolerance than did control mice.
To investigate whether these benefits persisted under nutritional conditions known to induce the metabolic syndrome - a group of symptoms associated with type 2 diabetes and cardiovascular disease - they fed both β7-negative mice and control mice a diet high in fat, sugar and sodium. The β7-negative mice remained lean, glucose tolerant, and did not develop hypertension or other typical results of a high-fat diet. The control mice did become obese, with elevated blood pressure and reduced glucose tolerance.
Experiments with a mouse model genetically programmed to develop elevated cholesterol found that blocking β7 expression in the bone marrow, where immune cells are generated, maintained normal lipid levels in the animals, in spite of their being fed a high-cholesterol diet. Mice with β7-negative marrow excreted more cholesterol, had improved glucose tolerance and were less likely to develop arterial plaques and other cardiovascular risk factors than were animals with normal bone marrow expression of β7.
A search for the cells responsible for β7's metabolic impact revealed that the protein's expression was highest in a group of T cells present in the lining of the small intestine. While β7 guides several types of immune cells to the intestines, only these β7-expressing intraepithelial T cells appear to regulate systemic metabolism. Swirski's team showed they do so by reducing levels of a protein called GLP-1, which normally increases metabolism by stimulating insulin secretion and glucose uptake.
Swirski explained that the metabolism-suppressing role of β7-positive intraepithelial T cells might have developed to prevent starvation under conditions of nutrient scarcity. "At times when the availability of food is uncertain, it would be advantageous to have a system that converts some of the energy ingested with food into fat. But during times of over-nutrition, such a system can backfire and lead to the cardiovascular disease that is so prevalent today," he says.
"Now we have a lot of questions to investigate - exactly how these cells limit the availability of GLP-1, whether people with a higher metabolism have fewer of these cells, how the cells' function may change over the course of a day or a lifetime, and whether blocking these cells can be beneficial in treating obesity, diabetes, hypertension and atherosclerosis." Swirski is an associate professor of Radiology at Harvard Medical School.
The co-lead authors of the Nature paper are Shun He, PhD, Florian Kahles, MD, and Sara Rattik, all at the MGH Center for Systems Biology. The Swirski lab (@SwirskiLab) also collaborated with Ralph Weissleder, MD, PhD, and Matthias Nahrendorf, MD, MGH Center for Systems Biology; Peter Libby, MD, Brigham and Women's Hospital; Carlos Fernandez-Hernando, PhD, Yale University, and Daniel Drucker, MD, Mount Sinai Hospital, Toronto. Support for the study includes National Institutes of Health grants R35 HL135752, R01 HL128264 and P01 HL131478 and the American Heart Association Established Investigator Award. Swirski is the Patricia and Scott Eston MGH Research Scholar.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $900 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2018 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."